STAT

Opinion: We need more answers about immunotherapy for the elderly

People older than 65 make up more than half of cancer patients. We need to learn how well immunotherapy works for them.
A cancer patient receives infusions of the immunotherapy Keytruda in New York City.

An old idea — using the body’s immune system to fight cancer cells, first proposed more than a century ago — has become one of the most promising approaches to treating cancer today. Immunotherapy is effective against a variety of cancers, with sometimes spectacular results. But I worry about how effective it is in people over age 65, who make up half of cancer patients.

We know that immunotherapy is by older individuals. But how well they. It causes the immune system to change and become less effective over time. Since immunotherapy involves harnessing the immune system to fight cancer, there are questions about how well it works in patients whose immune systems are changing.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: Senate Drug Shortage Bill Would Pay Hospitals Bonuses For Good Contracting Practices
A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a steady supply.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About GLP-1 Spending, Biosimilar Patient Costs, And More
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks